Chugai Pharmaceutical stock loses 0.38 percent pre-market to EUR 34.48
Published on 10/08/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 8, 2026, Chugai Pharmaceutical stock was quoted at EUR 34.48 pre-market by Lang & Schwarz at 7:43 a.m. CEST, down 0.38 percent versus the prior close at Lang & Schwarz of EUR 34.61 on October 7, 2026.
Pre-market trading
The bid was EUR 34.28 and the ask was EUR 34.67 at Lang & Schwarz. The quote was EUR 34.48 at 7:43 a.m. CEST on October 8, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.
Earlier pipeline development
On September 28, 2026, Chugai said it would discontinue clinical development of emugrobart, also known as GYM329, for obesity, according to a report by finanzen.ch. The report said the decision followed an interim analysis of the Phase II GYMINDA study, in which the predefined objectives for clinically meaningful additional weight loss were considered unlikely to be achieved. Chugai said the rights to emugrobart would return to the company. It also planned to prepare a possible resumption of development for spinal muscular atrophy and examine potential out-licensing opportunities.
